AbbVie Inc. (ABBV) KPIs and segments
Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của AbbVie · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của AbbVie: 58 chỉ số vận hành, trong đó có Total Net Revenues — Worldwide, Net Revenues by Country và Long-Lived Assets by Geographic Region, lấy từ 126 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1 | |||||||||||||
Total Net Revenues — Worldwide ($M)($M)4 | 16,990 | 15,002 | 16,618 | 15,776 | 15,423 | 13,343 | 15,102 | 14,460 | 14,462 | 12,310 | 14,301 | 13,927 | |
Total Net Revenues — United States ($M)($M)1 | 12,861 | 10,969 | 12,794 | 12,068 | 11,762 | 9,979 | 11,734 | 11,148 | 11,106 | 9,041 | 11,110 | 10,852 | |
United States — Reported revenue growth YoY (%)(%) | 9.3% | 9.9% | 9.0% | 8.2% | 5.9% | 10.4% | 5.6% | 2.7% | 3.6% | -1.7% | -8.9% | -7.7% | |
Total Net Revenues — International ($M)($M)2 | 4,129 | 4,033 | 3,824 | 3,708 | 3,661 | 3,364 | 3,368 | 3,312 | 3,356 | 3,269 | 3,191 | 3,075 | |
International — Reported revenue growth YoY (%)(%) | 12.8% | 19.9% | 13.5% | 12.0% | 9.1% | 2.9% | 5.6% | 7.7% | 6.8% | 8.1% | 8.9% | 0.8% | |
International — Operational (constant-currency) revenue growth YoY (%)(%) | 10.2% | 11.4% | 11.0% | 9.0% | 8.4% | 8.3% | 7.8% | 12.4% | 12.7% | 11.6% | 9.0% | 1.4% | |
Worldwide — Reported revenue growth YoY (%)(%) | 10.2% | 12.4% | 10.0% | 9.1% | 6.6% | 8.4% | 5.6% | 3.8% | 4.3% | 0.7% | -5.4% | -6.0% | |
Worldwide — Operational (constant-currency) revenue growth YoY (%)(%) | 9.5% | 10.3% | 9.5% | 8.4% | 6.5% | 9.8% | 6.1% | 4.9% | 5.6% | 1.6% | -5.4% | -5.8% | |
Immunology Portfolio — Worldwide net revenues ($M)($M)7 | 8,786 | 7,290 | 8,626 | 7,885 | 7,631 | 6,264 | 7,294 | 7,046 | 6,971 | 5,371 | 6,953 | 6,783 | |
Immunology Portfolio — U.S. net revenues ($M)($M)1 | 6,957 | 5,537 | 6,961 | 6,263 | 6,097 | 4,883 | 5,905 | 5,713 | 5,717 | 4,152 | 5,774 | 5,696 | |
Immunology Portfolio — U.S. reported growth YoY (%)(%) | 14.1% | 13.4% | 17.9% | 9.6% | 6.7% | 17.6% | 2.2% | 0.3% | -0.2% | -8.5% | -17.2% | -14.7% | |
Immunology Portfolio — International net revenues ($M)($M)2 | 1,829 | 1,753 | 1,665 | 1,622 | 1,534 | 1,381 | 1,389 | 1,333 | 1,254 | 1,219 | 1,179 | 1,087 | |
Immunology Portfolio — International reported growth YoY (%)(%) | 19.2% | 26.9% | 19.7% | 21.7% | 22.3% | 13.4% | 17.8% | 22.7% | 15.9% | 16.0% | 24.3% | 12.1% | |
Immunology Portfolio — International operational (constant-currency) growth YoY (%)(%) | 16.8% | 17.3% | 16.8% | 17.9% | 20.7% | 20.1% | 20.2% | 28.4% | 23.5% | 20.5% | 24.0% | 11.9% | |
Immunology Portfolio — Worldwide reported growth YoY (%)(%) | 15.1% | 16.4% | 18.3% | 11.9% | 9.5% | 16.6% | 4.9% | 3.9% | 2.3% | -3.9% | -12.3% | -11.3% | |
Immunology Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%) | 14.6% | 14.3% | 17.7% | 11.2% | 9.2% | 18.1% | 5.3% | 4.8% | 3.5% | -3.1% | -12.3% | -11.3% | |
Skyrizi (risankizumab) — Worldwide net revenues ($M)($M)4 | 5,505 | 4,483 | 5,006 | 4,708 | 4,423 | 3,425 | 3,778 | 3,205 | 2,727 | 2,008 | 2,394 | 2,126 | |
Skyrizi (risankizumab) — U.S. net revenues ($M)($M)1 | 4,767 | 3,775 | 4,355 | 4,085 | 3,843 | 2,919 | 3,312 | 2,778 | 2,340 | 1,656 | 2,105 | 1,875 | |
Skyrizi (risankizumab) — U.S. reported growth YoY (%)(%) | 24.0% | 29.3% | 31.5% | 47.0% | 64.3% | 76.2% | 57.3% | 48.3% | 43.2% | 45.3% | 50.0% | 53.5% | |
Skyrizi (risankizumab) — International net revenues ($M)($M)2 | 738 | 708 | 651 | 623 | 580 | 506 | 466 | 427 | 387 | 352 | 289 | 251 | |
Skyrizi (risankizumab) — International reported growth YoY (%)(%) | 27.3% | 39.8% | 39.8% | 45.9% | 49.7% | 43.9% | 61.1% | 70.0% | 55.5% | 59.4% | 67.5% | 42.5% | |
Skyrizi (risankizumab) — International operational (constant-currency) growth YoY (%)(%) | 24.2% | 28.0% | 35.1% | 40.2% | 47.2% | 52.3% | 62.4% | 75.7% | 61.8% | 61.6% | 64.4% | 40.7% | |
Skyrizi (risankizumab) — Worldwide reported growth YoY (%)(%) | 24.4% | 30.9% | 32.5% | 46.8% | 62.2% | 70.5% | 57.7% | 50.8% | 44.8% | 47.6% | 51.9% | 52.1% | |
Skyrizi (risankizumab) — Worldwide operational (constant-currency) growth YoY (%)(%) | 24.0% | 29.2% | 31.9% | 46.0% | 61.8% | 72.0% | 57.9% | 51.5% | 45.6% | 48.0% | 51.6% | 51.9% | |
Rinvoq (upadacitinib) — Worldwide net revenues ($M)($M)4 | 2,525 | 2,119 | 2,374 | 2,184 | 2,028 | 1,718 | 1,834 | 1,614 | 1,430 | 1,093 | 1,255 | 1,110 | |
Rinvoq (upadacitinib) — U.S. net revenues ($M)($M)1 | 1,765 | 1,405 | 1,709 | 1,559 | 1,452 | 1,220 | 1,347 | 1,170 | 1,017 | 725 | 929 | 801 | |
Rinvoq (upadacitinib) — U.S. reported growth YoY (%)(%) | 21.6% | 15.1% | 26.9% | 33.3% | 42.7% | 68.3% | 45.0% | 45.9% | 57.9% | 61.4% | 63.9% | 59.0% | |
Rinvoq (upadacitinib) — International net revenues ($M)($M)2 | 760 | 714 | 665 | 625 | 576 | 498 | 487 | 444 | 413 | 368 | 326 | 309 | |
Rinvoq (upadacitinib) — International reported growth YoY (%)(%) | 31.9% | 43.4% | 36.4% | 40.7% | 39.6% | 35.3% | 49.5% | 44.0% | 51.1% | 55.3% | 60.2% | 61.8% | |
Rinvoq (upadacitinib) — International operational (constant-currency) growth YoY (%)(%) | 29.2% | 32.6% | 33.2% | 36.5% | 37.5% | 42.8% | 53.1% | 51.6% | 62.6% | 62.8% | 59.8% | 61.2% | |
Rinvoq (upadacitinib) — Worldwide reported growth YoY (%)(%) | 24.5% | 23.3% | 29.5% | 35.3% | 41.8% | 57.2% | 46.2% | 45.3% | 55.8% | 59.3% | 62.9% | 59.8% | |
Rinvoq (upadacitinib) — Worldwide operational (constant-currency) growth YoY (%)(%) | 23.7% | 20.2% | 28.6% | 34.1% | 41.2% | 59.7% | 47.1% | 47.4% | 59.2% | 61.9% | 62.8% | 59.6% | |
Humira (adalimumab) — Worldwide net revenues ($M)($M)4 | 756 | 688 | 1,246 | 993 | 1,180 | 1,121 | 1,682 | 2,227 | 2,814 | 2,270 | 3,304 | 3,547 | |
Humira (adalimumab) — U.S. net revenues ($M)($M)1 | 425 | 357 | 897 | 619 | 802 | 744 | 1,246 | 1,765 | 2,360 | 1,771 | 2,740 | 3,020 | |
Humira (adalimumab) — U.S. reported growth YoY (%)(%) | -47.0% | -52.0% | -27.9% | -65.0% | -66.0% | -58.0% | -54.5% | -41.6% | -31.6% | -39.9% | -45.3% | -39.1% | |
Humira (adalimumab) — International net revenues ($M)($M)2 | 331 | 331 | 349 | 374 | 378 | 377 | 436 | 462 | 454 | 499 | 564 | 527 | |
Humira (adalimumab) — International reported growth YoY (%)(%) | -12.5% | -12.3% | -20.3% | -18.9% | -16.8% | -24.4% | -22.7% | -12.4% | -18.9% | -15.8% | -1.5% | -12.6% | |
Humira (adalimumab) — International operational (constant-currency) growth YoY (%)(%) | -13.2% | -17.4% | -21.0% | -20.5% | -17.2% | -19.5% | -20.5% | -7.8% | -12.5% | -11.6% | -1.0% | -12.2% | |
Humira (adalimumab) — Worldwide reported growth YoY (%)(%) | -35.9% | -38.6% | -25.9% | -55.4% | -58.1% | -50.6% | -49.1% | -37.2% | -29.8% | -35.9% | -40.8% | -36.2% | |
Humira (adalimumab) — Worldwide operational (constant-currency) growth YoY (%)(%) | -36.1% | -40.3% | -26.1% | -55.7% | -58.2% | -49.5% | -48.7% | -36.5% | -28.9% | -35.2% | -40.7% | -36.2% | |
Neuroscience Portfolio — Worldwide net revenues ($M)($M)11 | 3,228 | 2,875 | 2,961 | 2,841 | 2,683 | 2,282 | 2,509 | 2,363 | 2,162 | 1,965 | 2,094 | 2,043 | |
Neuroscience Portfolio — U.S. net revenues ($M)($M)1 | 2,771 | 2,459 | 2,572 | 2,463 | 2,333 | 1,972 | 2,210 | 2,088 | 1,895 | 1,714 | 1,861 | 1,817 | |
Neuroscience Portfolio — U.S. reported growth YoY (%)(%) | 18.8% | 24.7% | 16.3% | 18.0% | 23.2% | 15.0% | 18.8% | 14.9% | 14.9% | 17.1% | 23.7% | 24.0% | |
Neuroscience Portfolio — International net revenues ($M)($M)2 | 457 | 416 | 389 | 378 | 350 | 310 | 299 | 275 | 267 | 251 | 233 | 226 | |
Neuroscience Portfolio — International reported growth YoY (%)(%) | 29.9% | 34.4% | 30.3% | 37.2% | 30.6% | 24.0% | 28.4% | 21.2% | 13.5% | 7.9% | 14.7% | 8.9% | |
Neuroscience Portfolio — International operational (constant-currency) growth YoY (%)(%) | 25.7% | 21.8% | 25.6% | 32.3% | 28.7% | 31.0% | 29.3% | 25.1% | 17.3% | 8.9% | 13.0% | 8.4% | |
Neuroscience Portfolio — Worldwide reported growth YoY (%)(%) | 20.3% | 26.0% | 17.9% | 20.2% | 24.2% | 16.1% | 19.8% | 15.6% | 14.7% | 15.9% | 22.6% | 22.1% | |
Neuroscience Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%) | 19.8% | 24.3% | 17.3% | 19.6% | 24.0% | 17.0% | 19.9% | 16.0% | 15.2% | 16.0% | 22.4% | 22.0% | |
Vraylar (cariprazine) — Worldwide net revenues ($M)($M)4 | 1,071 | 905 | 1,022 | 934 | 900 | 765 | 924 | 875 | 774 | 694 | 789 | 751 | |
Vraylar (cariprazine) — U.S. net revenues ($M)($M)1 | 1,068 | 902 | 1,020 | 931 | 898 | 763 | 922 | 873 | 773 | 692 | 788 | 750 | |
Vraylar (cariprazine) — U.S. reported growth YoY (%)(%) | 18.9% | 18.2% | 10.5% | 6.7% | 16.2% | 10.3% | 17.1% | 16.5% | 17.5% | 23.5% | 39.6% | 35.2% | |
Vraylar (cariprazine) — International net revenues ($M)($M)2 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | |
Vraylar (cariprazine) — International reported growth YoY (%)(%) | 30.1% | 67.6% | 21.7% | 31.5% | 72.8% | 13.1% | 25.8% | 49.3% | 68.8% | ||||
Vraylar (cariprazine) — International operational (constant-currency) growth YoY (%)(%) | 28.5% | 58.9% | 24.5% | 32.3% | 76.8% | 20.2% | 26.4% | 51.9% | 69.2% | ||||
Vraylar (cariprazine) — Worldwide reported growth YoY (%)(%) | 18.9% | 18.4% | 10.5% | 6.7% | 16.3% | 10.3% | 17.1% | 16.6% | 17.6% | 23.6% | 39.8% | 35.4% | |
Vraylar (cariprazine) — Worldwide operational (constant-currency) growth YoY (%)(%) | 18.9% | 18.4% | 10.5% | 6.7% | 16.3% | 10.3% | 17.1% | 16.6% | 17.6% | 23.6% | 39.8% | 35.4% | |
Botox Therapeutic (onabotulinumtoxinA) — Worldwide net revenues ($M)($M)4 | 1,042 | 1,009 | 990 | 985 | 928 | 866 | 873 | 848 | 814 | 748 | 776 | 748 | |
Botox Therapeutic (onabotulinumtoxinA) — U.S. net revenues ($M)($M)1 | 864 | 842 | 828 | 825 | 775 | 723 | 730 | 708 | 669 | 611 | 649 | 626 | |
Botox Therapeutic (onabotulinumtoxinA) — U.S. reported growth YoY (%)(%) | 11.4% | 16.5% | 13.5% | 16.6% | 15.9% | 18.2% | 12.4% | 13.1% | 8.9% | 4.1% | 5.7% | 7.2% | |
Botox Therapeutic (onabotulinumtoxinA) — International net revenues ($M)($M)2 | 178 | 167 | 162 | 160 | 153 | 143 | 143 | 140 | 145 | 137 | 127 | 122 | |
Botox Therapeutic (onabotulinumtoxinA) — International reported growth YoY (%)(%) | 16.2% | 16.3% | 13.1% | 13.4% | 5.7% | 4.8% | 13.2% | 14.6% | 7.9% | 3.9% | 11.5% | 6.5% | |
Botox Therapeutic (onabotulinumtoxinA) — International operational (constant-currency) growth YoY (%)(%) | 12.5% | 6.7% | 10.7% | 11.3% | 6.0% | 11.4% | 16.3% | 20.7% | 13.0% | 6.3% | 11.9% | 8.6% | |
Botox Therapeutic (onabotulinumtoxinA) — Worldwide reported growth YoY (%)(%) | 12.2% | 16.5% | 13.4% | 16.1% | 14.1% | 15.8% | 12.5% | 13.4% | 8.7% | 4.1% | 6.6% | 7.1% | |
Botox Therapeutic (onabotulinumtoxinA) — Worldwide operational (constant-currency) growth YoY (%)(%) | 11.6% | 14.9% | 13.0% | 15.8% | 14.2% | 17.0% | 13.0% | 14.4% | 9.6% | 4.5% | 6.7% | 7.4% | |
Ubrelvy (ubrogepant) — Worldwide net revenues ($M)($M)4 | 392 | 339 | 339 | 354 | 338 | 240 | 303 | 269 | 231 | 203 | 234 | 233 | |
Ubrelvy (ubrogepant) — U.S. net revenues ($M)($M)1 | 379 | 330 | 332 | 344 | 330 | 233 | 296 | 261 | 227 | 197 | 229 | 230 | |
Ubrelvy (ubrogepant) — U.S. reported growth YoY (%)(%) | 15.0% | 41.7% | 12.3% | 31.4% | 46.5% | 17.6% | 28.9% | 13.6% | 16.6% | 31.5% | 16.9% | 43.7% | |
Ubrelvy (ubrogepant) — International net revenues ($M)($M)2 | 13 | 9 | 7 | 10 | 8 | 7 | 7 | 8 | 4 | 6 | 5 | 3 | |
Ubrelvy (ubrogepant) — International reported growth YoY (%)(%) | 54.9% | 29.2% | -3.7% | 34.1% | 73.9% | 23.3% | 65.3% | 81.6% | |||||
Ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%)(%) | 52.5% | 22.9% | -3.0% | 34.2% | 76.7% | 29.3% | 66.2% | 82.3% | |||||
Ubrelvy (ubrogepant) — Worldwide reported growth YoY (%)(%) | 16.0% | 41.4% | 12.0% | 31.5% | 47.1% | 17.8% | 29.6% | 15.3% | 17.5% | 33.8% | 18.9% | 45.6% | |
Ubrelvy (ubrogepant) — Worldwide operational (constant-currency) growth YoY (%)(%) | 15.9% | 41.2% | 12.0% | 31.5% | 47.2% | 18.0% | 29.6% | 15.3% | 17.5% | 33.8% | 18.9% | 45.6% | |
Qulipta (atogepant) — Worldwide net revenues ($M)($M)4 | 350 | 296 | 288 | 288 | 267 | 193 | 201 | 176 | 150 | 131 | 114 | 132 | |
Qulipta (atogepant) — U.S. net revenues ($M)($M)1 | 289 | 250 | 245 | 252 | 237 | 172 | 186 | 168 | 146 | 128 | 113 | 131 | |
Qulipta (atogepant) — U.S. reported growth YoY (%)(%) | 22.1% | 45.4% | 30.9% | 50.2% | 62.8% | 34.2% | 65.7% | 28.3% | 52.8% | 94.5% | |||
Qulipta (atogepant) — International net revenues ($M)($M) | 61 | 46 | 43 | 36 | 30 | 21 | 15 | 8 | 4 | 3 | 1 | 1 | |
Qulipta (atogepant) — Worldwide reported growth YoY (%)(%) | 30.9% | 53.6% | 42.6% | 64.1% | 77.5% | 47.6% | 76.4% | 33.6% | 56.3% | 97.7% | |||
Qulipta (atogepant) — Worldwide operational (constant-currency) growth YoY (%)(%) | 30.3% | 51.3% | 41.8% | 63.1% | 76.9% | 48.3% | 76.2% | 33.6% | 56.3% | 97.7% | |||
Vyalev (foscarbidopa/foslevodopa) — Worldwide net revenues ($M)($M)2 | 256 | 201 | 183 | 138 | 98 | 63 | 44 | 28 | 18 | 9 | |||
Vyalev (foscarbidopa/foslevodopa) — U.S. net revenues ($M)($M) | 128 | 89 | 86 | 53 | 22 | 6 | 1 | 0 | 0 | 0 | |||
Vyalev (foscarbidopa/foslevodopa) — International net revenues ($M)($M) | 128 | 112 | 97 | 85 | 76 | 57 | 43 | 28 | 18 | 9 | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide net revenues ($M)($M)4 | 92 | 96 | 97 | 96 | 108 | 111 | 113 | 115 | 115 | 118 | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M)($M)1 | 17 | 16 | 20 | 20 | 24 | 24 | 23 | 25 | 23 | 25 | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. reported growth YoY (%)(%) | -31.6% | -29.9% | -13.6% | -19.4% | 2.8% | -4.7% | -2.6% | -2.6% | 3.8% | 10.6% | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International net revenues ($M)($M)2 | 75 | 80 | 77 | 76 | 84 | 87 | 90 | 90 | 92 | 93 | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International reported growth YoY (%)(%) | -10.4% | -9.0% | -13.7% | -16.0% | -8.1% | -7.1% | -3.2% | -2.7% | 9.0% | 6.6% | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International operational (constant-currency) growth YoY (%)(%) | -14.9% | -13.8% | -16.3% | -11.7% | -9.7% | -6.4% | -1.7% | -3.7% | 4.2% | 2.3% | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide reported growth YoY (%)(%) | -15.1% | -13.5% | -13.7% | -16.7% | -5.8% | -6.6% | -3.1% | -2.7% | 7.9% | 7.4% | |||
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)(%) | -18.6% | -17.3% | -15.7% | -13.3% | -7.0% | -6.0% | -1.9% | -3.5% | 4.1% | 4.0% | |||
Other Neuroscience — Worldwide net revenues ($M)($M)4 | 117 | 125 | 47 | 46 | 152 | 155 | 56 | 56 | 62 | 65 | 63 | 61 | |
Other Neuroscience — U.S. net revenues ($M)($M)1 | 43 | 46 | 44 | 42 | 71 | 75 | 51 | 54 | 57 | 61 | 59 | 55 | |
Other Neuroscience — U.S. reported growth YoY (%)(%) | -38.6% | -38.9% | -13.9% | -21.7% | -11.4% | -9.5% | -11.7% | -4.1% | -10.1% | -18.5% | 4.2% | -31.9% | |
Other Neuroscience — International net revenues ($M)($M)2 | 74 | 79 | 3 | 4 | 81 | 80 | 5 | 2 | 5 | 4 | 4 | 6 | |
Other Neuroscience — International reported growth YoY (%)(%) | -8.9% | -1.5% | -20.1% | 92.3% | -23.3% | -1.0% | 61.7% | 6.2% | |||||
Other Neuroscience — International operational (constant-currency) growth YoY (%)(%) | -12.4% | -11.7% | -19.0% | 94.0% | -21.3% | 6.5% | 62.5% | 9.6% | |||||
Other Neuroscience — Worldwide reported growth YoY (%)(%) | -22.7% | -19.6% | -14.4% | -17.3% | -12.3% | -8.9% | 50.9% | 36.4% | 16.6% | -6.9% | 8.5% | -29.9% | |
Other Neuroscience — Worldwide operational (constant-currency) growth YoY (%)(%) | -24.6% | -24.8% | -14.3% | -17.2% | -12.2% | -8.4% | 50.4% | 37.1% | 17.5% | -6.7% | 8.6% | -29.7% | |
Oncology Portfolio — Worldwide net revenues ($M)($M)9 | 1,650 | 1,631 | 1,664 | 1,682 | 1,676 | 1,633 | 1,691 | 1,687 | 1,634 | 1,543 | 1,509 | 1,512 | |
Oncology Portfolio — U.S. net revenues ($M)($M)1 | 936 | 882 | 997 | 1,030 | 1,026 | 1,027 | 1,102 | 1,113 | 1,037 | 967 | 971 | 973 | |
Oncology Portfolio — U.S. reported growth YoY (%)(%) | -8.7% | -14.1% | -9.6% | -7.4% | -1.0% | 6.0% | 13.4% | 14.4% | 11.3% | 7.3% | -12.3% | -12.3% | |
Oncology Portfolio — International net revenues ($M)($M)2 | 714 | 749 | 667 | 652 | 650 | 606 | 589 | 574 | 597 | 576 | 538 | 539 | |
Oncology Portfolio — International reported growth YoY (%)(%) | 9.9% | 23.4% | 13.6% | 13.4% | 8.7% | 5.4% | 9.4% | 6.5% | 9.3% | 12.1% | 2.9% | -0.4% | |
Oncology Portfolio — International operational (constant-currency) growth YoY (%)(%) | 7.6% | 15.7% | 10.8% | 10.4% | 8.3% | 10.0% | 11.8% | 10.3% | 13.8% | 14.3% | 2.3% | -1.0% | |
Oncology Portfolio — Worldwide reported growth YoY (%)(%) | -1.5% | -0.2% | -1.5% | -0.3% | 2.6% | 5.8% | 12.0% | 11.6% | 10.5% | 9.0% | -7.4% | -8.4% | |
Oncology Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%) | -2.4% | -3.0% | -2.5% | -1.3% | 2.4% | 7.5% | 12.9% | 13.0% | 12.2% | 9.8% | -7.6% | -8.6% | |
Venclexta (venetoclax) — Worldwide net revenues ($M)($M)4 | 771 | 770 | 710 | 726 | 691 | 665 | 655 | 677 | 637 | 614 | 589 | 590 | |
Venclexta (venetoclax) — U.S. net revenues ($M)($M)1 | 369 | 341 | 332 | 341 | 321 | 312 | 313 | 340 | 300 | 281 | 276 | 281 | |
Venclexta (venetoclax) — U.S. reported growth YoY (%)(%) | 14.8% | 9.2% | 6.2% | 7.4% | 11.0% | 13.0% | 21.5% | 12.8% | 6.2% | 3.1% | 8.1% | ||
Venclexta (venetoclax) — International net revenues ($M)($M)2 | 402 | 429 | 378 | 385 | 370 | 353 | 342 | 337 | 337 | 333 | 313 | 309 | |
Venclexta (venetoclax) — International reported growth YoY (%)(%) | 8.8% | 21.4% | 10.8% | 14.3% | 9.5% | 6.0% | 9.3% | 8.9% | 10.4% | 21.9% | 26.4% | 21.1% | |
Venclexta (venetoclax) — International operational (constant-currency) growth YoY (%)(%) | 5.0% | 10.1% | 6.6% | 10.0% | 9.1% | 13.4% | 13.2% | 15.4% | 18.4% | 26.1% | 25.1% | 19.9% | |
Venclexta (venetoclax) — Worldwide reported growth YoY (%)(%) | 11.6% | 15.7% | 8.6% | 7.1% | 8.5% | 8.3% | 11.0% | 14.8% | 11.5% | 14.2% | 14.3% | 14.6% | |
Venclexta (venetoclax) — Worldwide operational (constant-currency) growth YoY (%)(%) | 9.6% | 9.7% | 6.4% | 4.9% | 8.3% | 12.3% | 13.0% | 18.2% | 15.8% | 16.3% | 13.7% | 14.0% | |
Imbruvica (ibrutinib) — Worldwide net revenues ($M)($M)4 | 532 | 556 | 671 | 706 | 754 | 738 | 848 | 828 | 833 | 838 | 903 | 908 | |
Imbruvica (ibrutinib) — U.S. net revenues ($M)($M)1 | 337 | 332 | 469 | 507 | 543 | 529 | 625 | 618 | 595 | 610 | 683 | 678 | |
Imbruvica (ibrutinib) — U.S. reported growth YoY (%)(%) | -37.8% | -37.4% | -25.0% | -17.9% | -8.9% | -13.3% | -8.6% | -8.9% | -10.6% | -4.3% | -18.6% | -20.2% | |
Imbruvica (ibrutinib) — International net revenues ($M)($M)2 | 195 | 224 | 202 | 199 | 211 | 209 | 223 | 210 | 238 | 228 | 220 | 230 | |
Imbruvica (ibrutinib) — International reported growth YoY (%)(%) | -7.8% | 7.2% | -9.0% | -5.8% | -11.2% | -8.2% | 1.2% | -8.4% | -1.4% | -5.1% | -20.0% | -19.6% | |
Imbruvica (ibrutinib) — International operational (constant-currency) growth YoY (%)(%) | -7.8% | 7.2% | -9.0% | -5.8% | -11.2% | -8.2% | 1.2% | -8.4% | -1.4% | -5.1% | -20.0% | -19.6% | |
Imbruvica (ibrutinib) — Worldwide reported growth YoY (%)(%) | -29.4% | -24.7% | -20.8% | -14.8% | -9.5% | -11.9% | -6.2% | -8.8% | -8.2% | -4.5% | -19.0% | -20.0% | |
Imbruvica (ibrutinib) — Worldwide operational (constant-currency) growth YoY (%)(%) | -29.4% | -24.7% | -20.8% | -14.8% | -9.5% | -11.9% | -6.2% | -8.8% | -8.2% | -4.5% | -19.0% | -20.0% | |
Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M)($M)4 | 211 | 198 | 182 | 170 | 159 | 179 | 148 | 139 | 128 | 64 | |||
Elahere (mirvetuximab soravtansine) — U.S. net revenues ($M)($M)1 | 161 | 160 | 154 | 150 | 138 | 165 | 146 | 139 | 128 | 64 | 0 | 0 | |
Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%)(%) | 17.1% | -2.9% | 5.0% | 8.6% | 8.0% | ||||||||
Elahere (mirvetuximab soravtansine) — International net revenues ($M)($M) | 50 | 38 | 28 | 20 | 21 | 14 | 2 | 0 | 0 | 0 | |||
Elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%)(%) | 33.1% | 10.7% | 22.6% | 23.3% | 24.2% | ||||||||
Elahere (mirvetuximab soravtansine) — Worldwide operational (constant-currency) growth YoY (%)(%) | 31.8% | 8.3% | 21.3% | 22.4% | 23.7% | ||||||||
Epkinly (epcoritamab) — Worldwide net revenues ($M)($M)2 | 103 | 83 | 81 | 69 | 70 | 51 | 40 | 43 | 36 | 27 | 17 | 14 | |
Epkinly (epcoritamab) — U.S. net revenues ($M)($M)1 | 64 | 51 | 52 | 44 | 49 | 36 | 36 | 31 | 29 | 22 | 14 | 14 | |
Epkinly (epcoritamab) — U.S. reported growth YoY (%)(%) | 62.4% | 22.1% | 23.8% | 30.8% | 57.4% | 66.7% | 48.9% | 13.4% | |||||
Epkinly (epcoritamab) — International net revenues ($M)($M) | 39 | 32 | 29 | 25 | 21 | 15 | 4 | 12 | 7 | 5 | 3 | 0 | |
Other Oncology — Worldwide net revenues ($M)($M)1 | 33 | 24 | 20 | 11 | 2 | 0 | 0 | 0 | 0 | ||||
Other Oncology — U.S. net revenues ($M)($M) | 33 | 24 | 20 | 11 | 2 | 0 | 0 | 0 | 0 | ||||
Aesthetics Portfolio — Worldwide net revenues ($M)($M)7 | 1,282 | 1,186 | 1,286 | 1,193 | 1,279 | 1,102 | 1,298 | 1,239 | 1,390 | 1,249 | 1,371 | 1,239 | |
Aesthetics Portfolio — U.S. net revenues ($M)($M)1 | 761 | 704 | 811 | 742 | 797 | 640 | 839 | 791 | 863 | 776 | 884 | 759 | |
Aesthetics Portfolio — U.S. reported growth YoY (%)(%) | -4.4% | 9.8% | -3.3% | -6.2% | -7.8% | -17.4% | -5.0% | 3.9% | 4.4% | -0.3% | 5.7% | ||
Aesthetics Portfolio — International net revenues ($M)($M)2 | 521 | 482 | 475 | 451 | 482 | 462 | 459 | 448 | 527 | 473 | 487 | 480 | |
Aesthetics Portfolio — International reported growth YoY (%)(%) | 8.1% | 4.5% | 3.3% | 0.8% | -8.5% | -2.4% | -5.6% | -6.4% | -5.4% | -9.4% | 7.6% | -11.4% | |
Aesthetics Portfolio — International operational (constant-currency) growth YoY (%)(%) | 5.0% | -1.5% | 2.5% | -0.6% | -8.3% | 1.6% | -3.2% | -1.6% | 0.4% | -5.5% | 9.0% | -9.7% | |
Aesthetics Portfolio — Worldwide reported growth YoY (%)(%) | 0.3% | 7.6% | -0.9% | -3.7% | -8.1% | -11.7% | -5.2% | -0.1% | 0.5% | -4.0% | 6.4% | -4.7% | |
Aesthetics Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%) | -0.9% | 5.1% | -1.2% | -4.2% | -8.0% | -10.2% | -4.4% | 1.8% | 2.8% | -2.5% | 6.9% | -4.0% | |
Botox Cosmetic (onabotulinumtoxinA) — Worldwide net revenues ($M)($M)4 | 728 | 668 | 717 | 637 | 692 | 556 | 687 | 671 | 729 | 633 | 718 | 620 | |
Botox Cosmetic (onabotulinumtoxinA) — U.S. net revenues ($M)($M)1 | 400 | 371 | 420 | 379 | 410 | 295 | 429 | 414 | 450 | 389 | 453 | 388 | |
Botox Cosmetic (onabotulinumtoxinA) — U.S. reported growth YoY (%)(%) | -2.4% | 25.8% | -2.1% | -8.4% | -8.7% | -24.3% | -5.2% | 6.5% | 7.1% | -4.9% | 7.3% | 5.0% | |
Botox Cosmetic (onabotulinumtoxinA) — International net revenues ($M)($M)2 | 328 | 297 | 297 | 258 | 282 | 261 | 258 | 257 | 279 | 244 | 265 | 232 | |
Botox Cosmetic (onabotulinumtoxinA) — International reported growth YoY (%)(%) | 16.4% | 13.9% | 14.7% | 0.7% | 0.9% | 6.9% | -2.5% | 10.9% | 5.2% | -2.2% | 20.6% | -13.3% | |
Botox Cosmetic (onabotulinumtoxinA) — International operational (constant-currency) growth YoY (%)(%) | 12.1% | 7.1% | 13.5% | -0.6% | 1.2% | 11.1% | -0.3% | 15.5% | 10.9% | 1.2% | 22.0% | -10.9% | |
Botox Cosmetic (onabotulinumtoxinA) — Worldwide reported growth YoY (%)(%) | 5.2% | 20.2% | 4.2% | -4.9% | -5.0% | -12.3% | -4.2% | 8.2% | 6.4% | -3.9% | 11.8% | -2.7% | |
Botox Cosmetic (onabotulinumtoxinA) — Worldwide operational (constant-currency) growth YoY (%)(%) | 3.4% | 17.0% | 3.8% | -5.4% | -4.9% | -10.7% | -3.4% | 9.9% | 8.6% | -2.6% | 12.3% | -1.7% | |
Juvederm Collection — Worldwide net revenues ($M)($M)4 | 245 | 232 | 249 | 253 | 260 | 231 | 279 | 258 | 343 | 297 | 334 | 321 | |
Juvederm Collection — U.S. net revenues ($M)($M)1 | 103 | 85 | 107 | 98 | 105 | 75 | 120 | 105 | 138 | 106 | 156 | 116 | |
Juvederm Collection — U.S. reported growth YoY (%)(%) | -2.0% | 12.2% | -11.0% | -7.5% | -23.6% | -29.0% | -22.5% | -10.2% | 10.4% | -13.2% | 20.5% | -6.4% | |
Juvederm Collection — International net revenues ($M)($M)2 | 142 | 147 | 142 | 155 | 155 | 156 | 159 | 153 | 205 | 191 | 178 | 205 | |
Juvederm Collection — International reported growth YoY (%)(%) | -8.6% | -5.3% | -10.5% | 1.4% | -24.4% | -18.5% | -10.9% | -25.1% | -15.6% | -18.1% | -8.0% | -9.8% | |
Juvederm Collection — International operational (constant-currency) growth YoY (%)(%) | -9.7% | -10.3% | -10.7% | -0.2% | -24.4% | -15.0% | -8.7% | -20.8% | -10.0% | -14.0% | -7.3% | -8.7% | |
Juvederm Collection — Worldwide reported growth YoY (%)(%) | -6.0% | 0.4% | -10.7% | -2.2% | -24.0% | -22.2% | -16.3% | -19.7% | -6.8% | -16.4% | 3.4% | -8.6% | |
Juvederm Collection — Worldwide operational (constant-currency) growth YoY (%)(%) | -6.6% | -2.9% | -10.8% | -3.2% | -24.0% | -20.0% | -15.1% | -16.9% | -3.1% | -13.7% | 3.8% | -7.9% | |
Other Aesthetics — Worldwide net revenues ($M)($M)4 | 309 | 286 | 320 | 303 | 327 | 315 | 332 | 310 | 318 | 319 | 319 | 298 | |
Other Aesthetics — U.S. net revenues ($M)($M)1 | 258 | 248 | 284 | 265 | 282 | 270 | 290 | 272 | 275 | 281 | 275 | 255 | |
Other Aesthetics — U.S. reported growth YoY (%)(%) | -8.3% | -8.4% | -1.8% | -2.3% | 1.6% | -3.5% | 5.2% | 6.4% | -2.3% | 13.7% | -3.3% | -4.0% | |
Other Aesthetics — International net revenues ($M)($M)2 | 51 | 38 | 36 | 38 | 45 | 45 | 42 | 38 | 43 | 38 | 44 | 43 | |
Other Aesthetics — International reported growth YoY (%)(%) | 14.1% | -15.7% | -14.5% | -0.8% | 5.8% | 18.1% | -2.3% | -10.0% | -11.7% | -3.7% | 12.6% | -8.1% | |
Other Aesthetics — International operational (constant-currency) growth YoY (%)(%) | 11.8% | -20.5% | -15.0% | -2.2% | 6.4% | 23.2% | 1.5% | -2.0% | -4.1% | 1.2% | 16.9% | -7.0% | |
Other Aesthetics — Worldwide reported growth YoY (%)(%) | -5.2% | -9.4% | -3.4% | -2.1% | 2.2% | -0.9% | 4.2% | 4.0% | -3.6% | 11.3% | -1.5% | -4.6% | |
Other Aesthetics — Worldwide operational (constant-currency) growth YoY (%)(%) | -5.5% | -10.1% | -3.5% | -2.3% | 2.3% | -0.3% | 4.7% | 5.1% | -2.5% | 12.0% | -1.0% | -4.4% | |
Other Key Products Portfolio — Worldwide net revenues ($M)($M)7 | 935 | 995 | 884 | 1,006 | 1,037 | 809 | 912 | 874 | 962 | 900 | 968 | 963 | |
Other Key Products Portfolio — U.S. net revenues ($M)($M)1 | 761 | 816 | 711 | 829 | 835 | 636 | 748 | 710 | 750 | 686 | 778 | 751 | |
Other Key Products Portfolio — U.S. reported growth YoY (%)(%) | -9.1% | 28.5% | -5.1% | 16.9% | 11.2% | -7.2% | -3.8% | -5.6% | 0.9% | -5.6% | -1.5% | -4.6% | |
Other Key Products Portfolio — International net revenues ($M)($M)2 | 174 | 179 | 173 | 177 | 202 | 173 | 164 | 164 | 212 | 214 | 190 | 212 | |
Other Key Products Portfolio — International reported growth YoY (%)(%) | -13.4% | 3.0% | 5.3% | 8.1% | -4.4% | -19.4% | -14.1% | -22.1% | 4.1% | 6.3% | -2.3% | 4.4% | |
Other Key Products Portfolio — International operational (constant-currency) growth YoY (%)(%) | -15.5% | -7.9% | 1.3% | 3.4% | -5.8% | -14.8% | -13.9% | -19.5% | 8.8% | 8.8% | -1.0% | 4.9% | |
Other Key Products Portfolio — Worldwide reported growth YoY (%)(%) | -9.9% | 23.0% | -3.2% | 15.2% | 7.8% | -10.1% | -5.8% | -9.3% | 1.6% | -3.0% | -1.7% | -2.8% | |
Other Key Products Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%) | -10.3% | 20.7% | -3.9% | 14.3% | 7.5% | -9.0% | -5.8% | -8.7% | 2.6% | -2.4% | -1.4% | -2.7% | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide net revenues ($M)($M)4 | 295 | 351 | 324 | 312 | 375 | 306 | 291 | 302 | 369 | 349 | 309 | 370 | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. net revenues ($M)($M)1 | 133 | 183 | 163 | 146 | 184 | 142 | 137 | 147 | 167 | 144 | 128 | 167 | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. reported growth YoY (%)(%) | -27.7% | 28.3% | 17.9% | -0.2% | 9.7% | -0.7% | 7.8% | -12.7% | -13.2% | -15.8% | -33.5% | -12.3% | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International net revenues ($M)($M)2 | 162 | 168 | 161 | 166 | 191 | 164 | 154 | 155 | 202 | 205 | 181 | 203 | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International reported growth YoY (%)(%) | -14.9% | 2.4% | 4.9% | 6.9% | -5.1% | -20.4% | -15.4% | -23.1% | 3.8% | 6.2% | -3.0% | 5.2% | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International operational (constant-currency) growth YoY (%)(%) | -16.9% | -8.6% | 0.8% | 2.1% | -6.5% | -15.8% | -15.1% | -20.5% | 8.8% | 9.0% | -1.5% | 5.8% | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide reported growth YoY (%)(%) | -21.2% | 14.5% | 11.0% | 3.5% | 1.6% | -12.3% | -5.8% | -18.4% | -4.7% | -4.1% | -18.5% | -3.5% | |
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide operational (constant-currency) growth YoY (%)(%) | -22.2% | 8.6% | 8.9% | 1.0% | 0.8% | -9.6% | -5.6% | -17.0% | -2.2% | -2.6% | -17.8% | -3.2% | |
Creon (pancrelipase) — Worldwide net revenues ($M)($M)3 | 345 | 361 | 385 | 368 | 404 | 355 | 388 | 338 | 372 | 285 | 376 | 305 | |
Creon (pancrelipase) — U.S. net revenues ($M)($M)1 | 345 | 361 | 385 | 368 | 404 | 355 | 388 | 338 | 372 | 285 | 376 | 305 | |
Creon (pancrelipase) — U.S. reported growth YoY (%)(%) | -14.7% | 1.8% | -0.8% | 9.1% | 8.4% | 24.6% | 3.3% | 10.6% | 32.1% | -6.6% | 11.5% | -9.1% | |
Creon (pancrelipase) — Worldwide reported growth YoY (%)(%) | -14.7% | 1.8% | -0.8% | 9.1% | 8.4% | 24.6% | 3.3% | 10.6% | 32.1% | -6.6% | 11.5% | -9.1% | |
Creon (pancrelipase) — Worldwide operational (constant-currency) growth YoY (%)(%) | -14.7% | 1.8% | -0.8% | 9.1% | 8.4% | 24.6% | 3.3% | 10.6% | 32.1% | -6.6% | 11.5% | -9.1% | |
Linzess/Constella (linaclotide) — Worldwide net revenues ($M)($M)2 | 295 | 283 | 175 | 326 | 258 | 148 | 233 | 234 | 221 | 266 | 283 | 288 | |
Linzess/Constella (linaclotide) — U.S. net revenues ($M)($M) | 283 | 272 | 163 | 315 | 247 | 139 | 223 | 225 | 211 | 257 | 274 | 279 | |
Linzess/Constella (linaclotide) — International net revenues ($M)($M) | 12 | 11 | 12 | 11 | 11 | 9 | 10 | 9 | 10 | 9 | 9 | 9 | |
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M)($M)9 | 580 | 509 | 514 | 506 | 646 | 525 | 533 | 538 | 585 | 605 | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. net revenues ($M)($M)1 | 286 | 221 | 226 | 221 | 358 | 240 | 239 | 227 | 314 | 310 | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. reported growth YoY (%)(%) | -19.7% | -8.0% | -5.7% | -2.6% | 12.8% | -22.9% | -21.8% | -29.2% | -6.9% | -14.0% | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — International net revenues ($M)($M)2 | 294 | 288 | 288 | 285 | 288 | 285 | 294 | 311 | 271 | 295 | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — International reported growth YoY (%)(%) | 1.6% | 1.3% | -2.4% | -8.0% | 7.3% | -3.5% | -4.7% | 7.6% | 7.2% | 13.1% | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — International operational (constant-currency) growth YoY (%)(%) | -0.4% | -1.0% | -1.5% | -2.0% | 9.8% | 1.2% | 0.2% | 10.3% | 6.7% | 13.9% | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%)(%) | -10.1% | -3.0% | -3.9% | -5.7% | 10.2% | -13.5% | -13.3% | -11.7% | -0.9% | -2.7% | |||
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)(%) | -11.0% | -4.2% | -3.4% | -2.2% | 11.4% | -11.2% | -10.9% | -10.4% | -1.1% | -2.4% | |||
Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M)($M)4 | 128 | 117 | 125 | 123 | 120 | 119 | 124 | 131 | 118 | 120 | |||
Ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M)($M)1 | 32 | 32 | 30 | 30 | 36 | 33 | 35 | 34 | 36 | 34 | |||
Ozurdex (dexamethasone intravitreal implant) — U.S. reported growth YoY (%)(%) | -10.4% | -4.9% | -12.6% | -12.1% | -3.2% | -2.3% | 4.2% | -13.7% | 3.0% | -4.5% | |||
Ozurdex (dexamethasone intravitreal implant) — International net revenues ($M)($M)2 | 96 | 85 | 95 | 93 | 84 | 86 | 89 | 97 | 82 | 86 | |||
Ozurdex (dexamethasone intravitreal implant) — International reported growth YoY (%)(%) | 14.1% | -0.3% | 5.8% | -3.8% | 3.0% | -0.3% | 4.6% | 27.9% | 17.0% | 22.3% | |||
Ozurdex (dexamethasone intravitreal implant) — International operational (constant-currency) growth YoY (%)(%) | 10.4% | -3.6% | 4.4% | 1.1% | 3.5% | 2.5% | 9.5% | 29.3% | 15.4% | 21.7% | |||
Ozurdex (dexamethasone intravitreal implant) — Worldwide reported growth YoY (%)(%) | 6.9% | -1.6% | 0.6% | -6.0% | 1.1% | -0.9% | 4.5% | 13.7% | 12.3% | 13.2% | |||
Ozurdex (dexamethasone intravitreal implant) — Worldwide operational (constant-currency) growth YoY (%)(%) | 4.3% | -4.0% | -0.4% | -2.4% | 1.4% | 1.1% | 8.0% | 14.6% | 11.3% | 12.8% | |||
Lumigan/Ganfort (bimatoprost) — Worldwide net revenues ($M)($M)4 | 104 | 97 | 103 | 106 | 119 | 116 | 103 | 91 | 92 | 91 | |||
Lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M)($M)1 | 47 | 42 | 52 | 48 | 58 | 58 | 42 | 29 | 31 | 28 | |||
Lumigan/Ganfort (bimatoprost) — U.S. reported growth YoY (%)(%) | -19.0% | -26.1% | 19.9% | 69.2% | 83.9% | -15.8% | -55.0% | -44.1% | -53.0% | ||||
Lumigan/Ganfort (bimatoprost) — International net revenues ($M)($M)2 | 57 | 55 | 51 | 58 | 61 | 58 | 61 | 62 | 61 | 63 | |||
Lumigan/Ganfort (bimatoprost) — International reported growth YoY (%)(%) | -6.6% | -6.0% | -15.4% | -6.8% | 0.9% | -7.0% | -11.2% | -7.6% | -9.9% | 2.7% | |||
Lumigan/Ganfort (bimatoprost) — International operational (constant-currency) growth YoY (%)(%) | -9.1% | -8.7% | -15.2% | -0.5% | 2.2% | -2.7% | -8.1% | -6.4% | -11.9% | 1.4% | |||
Lumigan/Ganfort (bimatoprost) — Worldwide reported growth YoY (%)(%) | -12.6% | -15.9% | -0.8% | 17.0% | 29.4% | 27.2% | -13.2% | -30.5% | -25.5% | -24.8% | |||
Lumigan/Ganfort (bimatoprost) — Worldwide operational (constant-currency) growth YoY (%)(%) | -13.9% | -17.3% | -0.7% | 21.4% | 30.2% | 30.2% | -11.4% | -29.9% | -26.6% | -25.5% | |||
Alphagan/Combigan (brimonidine) — Worldwide net revenues ($M)($M)4 | 54 | 47 | 36 | 60 | 78 | 62 | 49 | 59 | 66 | 70 | |||
Alphagan/Combigan (brimonidine) — U.S. net revenues ($M)($M)1 | 18 | 9 | 0 | 26 | 41 | 26 | 13 | 15 | 31 | 30 | |||
Alphagan/Combigan (brimonidine) — U.S. reported growth YoY (%)(%) | -54.8% | -67.4% | -91.6% | 68.5% | 33.6% | -15.3% | -59.5% | -47.0% | -26.8% | -16.0% | |||
Alphagan/Combigan (brimonidine) — International net revenues ($M)($M)2 | 36 | 38 | 36 | 34 | 37 | 36 | 36 | 44 | 35 | 40 | |||
Alphagan/Combigan (brimonidine) — International reported growth YoY (%)(%) | -4.5% | 6.8% | -3.1% | -21.4% | 6.8% | -10.0% | 9.1% | 1.9% | 7.2% | 10.1% | |||
Alphagan/Combigan (brimonidine) — International operational (constant-currency) growth YoY (%)(%) | -5.4% | 4.7% | -0.2% | -15.4% | 10.2% | -4.5% | 20.5% | 6.9% | 9.8% | 17.3% | |||
Alphagan/Combigan (brimonidine) — Worldwide reported growth YoY (%)(%) | -30.5% | -24.7% | -25.6% | 1.9% | 19.2% | -12.3% | -23.7% | -17.7% | -11.7% | -3.1% | |||
Alphagan/Combigan (brimonidine) — Worldwide operational (constant-currency) growth YoY (%)(%) | -30.9% | -25.9% | -23.5% | 6.3% | 21.0% | -9.2% | -17.8% | -14.7% | -10.5% | 0.4% | |||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M)($M)4 | 114 | 21 | 32 | 57 | 128 | 117 | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. net revenues ($M)($M)1 | 102 | 8 | 18 | 44 | 117 | 104 | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%)(%) | -13.7% | -92.5% | -77.3% | -44.1% | 13.5% | -20.7% | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International net revenues ($M)($M)2 | 12 | 13 | 14 | 13 | 11 | 13 | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International reported growth YoY (%)(%) | 14.9% | 2.1% | -18.9% | -1.4% | 44.7% | 35.0% | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International operational (constant-currency) growth YoY (%)(%) | 19.7% | 8.1% | -14.5% | 4.1% | 51.4% | 42.1% | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide reported growth YoY (%)(%) | -11.3% | -82.2% | -67.0% | -38.1% | 15.6% | -17.0% | |||||||
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide operational (constant-currency) growth YoY (%)(%) | -10.9% | -81.5% | -66.2% | -37.3% | 16.1% | -16.5% | |||||||
Other Eye Care — Worldwide net revenues ($M)($M)4 | 294 | 248 | 250 | 217 | 329 | 228 | 257 | 257 | 617 | 207 | |||
Other Eye Care — U.S. net revenues ($M)($M)1 | 189 | 138 | 144 | 117 | 223 | 123 | 149 | 149 | 481 | 114 | |||
Other Eye Care — U.S. reported growth YoY (%)(%) | -14.9% | 12.3% | -4.3% | -21.4% | 20.9% | 1.7% | 18.9% | -4.8% | -2.5% | 16.3% | |||
Other Eye Care — International net revenues ($M)($M)2 | 105 | 110 | 106 | 100 | 106 | 105 | 108 | 108 | 136 | 93 | |||
Other Eye Care — International reported growth YoY (%)(%) | -1.5% | 4.7% | -1.7% | -7.1% | 15.4% | -2.0% | -10.1% | 5.9% | 9.7% | 11.9% | |||
Other Eye Care — International operational (constant-currency) growth YoY (%)(%) | -2.3% | 3.5% | 0.9% | -0.2% | 20.3% | 4.2% | -6.1% | 9.3% | 9.3% | 12.0% | |||
Other Eye Care — Worldwide reported growth YoY (%)(%) | -10.5% | 8.8% | -3.2% | -15.4% | 18.4% | 4.8% | 2.6% | 14.2% | |||||
Other Eye Care — Worldwide operational (constant-currency) growth YoY (%)(%) | -10.8% | 8.2% | -2.1% | -12.5% | 20.6% | 2.8% | 6.7% | 1.5% | 2.4% | 14.2% | |||
Research and Development (R&D) Expense — GAAP ($M)($M)3 | 2,344 | 2,472 | 2,579 | 2,319 | 2,131 | 2,067 | 6,774 | 2,130 | 1,948 | 1,939 | 1,927 | 1,723 | |
Adjusted R&D Expense — Non-GAAP ($M)($M) | 2,314 | 2,268 | 18.3 | 2,256 | 2,115 | 14.2 | 20.2 | 2,055 | 1,917 | 14.8 | 17.2 | 15.7 | |
GAAP R&D Expense % of Net Revenues (%)(%) | 13.8% | 16.5% | 15.5% | 14.7% | 13.8% | 15.5% | 44.9% | 14.7% | 13.5% | 15.8% | |||
Adjusted R&D Expense % of Net Revenues — Non-GAAP (%)(%) | 13.6% | 15.1% | 15.4% | 14.3% | 13.7% | 15.4% | 15.1% | 14.2% | 13.3% | 14.7% | |||
Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M)($M)3 | 291 | 744 | -3,149 | 2,680 | 823 | 248 | -208 | 82 | 937 | 164 | 86 | 66 | |
Development and Regulatory Milestones Recognized in R&D ($M)($M) | 146 | 41 | 23 | 65 | 118 | 2 | 35 | 0 | 10 | 85 | 96 | 22 | |
Acquired IPR&D and Milestones % of Net Revenues (%)(%) | 1.7% | 5.0% | 7.6% | 17.0% | 5.3% | 1.9% | 10.4% | 0.6% | 6.5% | 1.3% | 2.0% | 0.5% | |
Acquired IPR&D and Milestones Unfavorable Impact to Diluted EPS ($/sh)($) | 0.17 | 0.41 | 0.71 | 1.50 | 0.42 | 0.13 | 0.88 | 0.04 | 0.52 | 0.08 | 0.15 | 0.04 | |
Janssen Biotech Collaboration (Imbruvica) — International Profit Share in Net Revenues ($M)($M)1 | 195 | 224 | 202 | 199 | 211 | 209 | 223 | 210 | 238 | 228 | 220 | 230 | |
Janssen U.S. Profit Share Recorded in AbbVie Cost of Products Sold ($M)($M) | 157 | 153 | 219 | 235 | 253 | 247 | 291 | 282 | 284 | 283 | 320 | 316 | |
Genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M)($M) | 298 | 284 | 274 | 286 | 262 | 242 | 257 | 263 | 243 | 227 | 228 | 225 | |
Adjusted Gross Margin Ratio — Non-GAAP (%)(%)1 | 84.7% | 83.6% | 83.6% | 83.9% | 84.4% | 84.1% | 83.8% | 84.4% | 85.2% | 82.9% | 83.9% | 83.5% | |
GAAP Gross Margin Ratio (%)(%) | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% | 70.9% | 66.7% | 60.1% | 53.4% | |
Adjusted Operating Margin Ratio — Non-GAAP (%)(%)1 | 48.3% | 40.8% | 38.3% | 30.9% | 44.3% | 42.3% | 34.7% | 46.7% | 42.6% | 42.2% | 43.8% | 46.7% | |
GAAP Operating Margin Ratio (%)(%) | 37.9% | 26.6% | 27.3% | 12.1% | 31.7% | 28.0% | 26.5% | 27.6% | 22.7% | 22.3% | 16.4% | ||
Adjusted SG&A Expense % of Net Revenues — Non-GAAP (%)(%)1 | 21.0% | 22.7% | 22.3% | 21.6% | 21.0% | 24.6% | 23.6% | 23.0% | 22.9% | 24.6% | 24.7% | 23.9% | |
GAAP SG&A Expense % of Net Revenues (%)(%) | 21.4% | 23.9% | 23.4% | 22.6% | 21.1% | 24.7% | 25.5% | 29.1% | 23.3% | 26.9% | 22.3% | 24.2% | |
Adjusted Effective Tax Rate — Non-GAAP (%)(%)2 | 14.7% | 15.4% | 18.3% | 24.5% | 16.2% | 14.2% | 20.2% | 16.2% | 18.8% | 14.8% | 17.2% | 15.7% | |
GAAP Effective Tax Rate (%)(%) | 15.5% | 32.9% | 32.0% | 73.7% | 39.4% | 22.4% | 99.0% | 25.0% | 36.0% | 21.8% | 32.1% | 8.8% | |
Effective Tax Rate on Specified Items (%)(%) | 13.7% | 11.3% | 7.0% | 14.9% | 8.6% | 10.3% | 45.4% | 11.9% | 8.7% | 10.8% | 13.4% | 18.9% | |
Adjusted After-Tax Earnings — Non-GAAP ($M)($M)6 | 6,491 | 4,711 | 4,830 | 3,306 | 5,278 | 4,370 | 3,844 | 5,327 | 4,710 | 4,120 | 4,959 | 5,250 | |
Reported After-Tax Earnings — GAAP ($M)($M) | 3,613 | 695 | 1,816 | 186 | 938 | 1,286 | -22 | 1,561 | 1,370 | 1,369 | 822 | 1,778 | |
Adjusted Pre-Tax Earnings — Non-GAAP ($M)($M) | 7,613 | 5,569 | 5,909 | 4,380 | 6,304 | 5,099 | 4,813 | 6,357 | 5,804 | 4,838 | 5,990 | 6,233 | |
Reported Pre-Tax Earnings — GAAP ($M)($M) | 4,278 | 1,039 | 2,668 | 714 | 1,554 | 1,661 | -2,269 | 2,084 | 2,146 | 1,755 | 1,212 | 1,953 | |
Adjusted Cost of Products Sold — Non-GAAP ($M)($M) | 2,598 | 2,462 | 5,909 | 2,547 | 2,413 | 5,099 | 4,813 | 2,251 | 2,135 | 4,838 | 5,990 | 6,233 | |
Adjusted SG&A Expense — Non-GAAP ($M)($M) | 3,574 | 3,401 | 1,080 | 3,412 | 3,239 | 726 | 970 | 3,326 | 3,315 | 715 | 1,029 | 980 | |
Adjusted Income Tax Expense — Non-GAAP ($M)($M) | 1,119 | 856 | 1,080 | 1,072 | 1,023 | 726 | 970 | 1,027 | 1,091 | 715 | 1,029 | 980 | |
Adjusted Diluted Earnings Per Share — Non-GAAP ($/sh)($)5 | 3.65 | 2.65 | 2.71 | 1.86 | 2.97 | 2.46 | 2.16 | 3 | 2.65 | 2.31 | 2.79 | 2.95 | |
Reported Diluted Earnings Per Share — GAAP ($/sh)($) | 2.03 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 | 0.88 | 0.77 | 0.77 | 0.46 | 1 | |
Total Specified Items — Pre-Tax ($M)($M) | 3,335 | 4,530 | 3,241 | 3,666 | 4,750 | 3,438 | 7,082 | 4,273 | 3,658 | 3,083 | 4,778 | 4,280 | |
Total Specified Items — Income Tax Impact ($M)($M) | 457 | 514 | 227 | 546 | 410 | 354 | 3,216 | 507 | 318 | 332 | 641 | 808 | |
Specified Item: Intangible Asset Amortization — Pre-Tax ($M)($M)2 | 1,689 | 1,748 | 1,784 | 1,871 | 1,864 | 1,858 | 1,896 | 1,888 | 1,947 | 1,891 | 1,889 | 2,039 | |
Intangible Asset Amortization — After-Tax ($M)($M) | 1,436 | 1,498 | 1,500 | 1,576 | 1,571 | 1,574 | 1,607 | 1,600 | 1,651 | 1,603 | 1,584 | 1,728 | |
Intangible Asset Amortization — Diluted EPS Impact ($/sh)($) | 0.81 | 0.85 | 0.85 | 0.89 | 0.89 | 0.89 | 0.90 | 0.89 | 0.93 | 0.90 | 0.89 | 0.98 | |
Specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M)($M)2 | 1,518 | 2,387 | 1,406 | 776 | 2,795 | 1,518 | 279 | 1,356 | 1,476 | 660 | 1,696 | 8 | |
Change in Fair Value of Contingent Consideration — After-Tax ($M)($M) | 1,479 | 2,325 | 1,368 | 755 | 2,709 | 1,477 | 271 | 1,321 | 1,438 | 643 | 1,655 | 8 | |
Change in Fair Value of Contingent Consideration — Diluted EPS Impact ($/sh)($) | 0.83 | 1.31 | 0.77 | 0.43 | 1.53 | 0.83 | 0.15 | 0.75 | 0.81 | 0.36 | 0.93 | ||
Contingent Consideration Liability — Total Level 3 Fair Value ($M)($M)8 | 27,495 | 27,039 | 25,374 | 24,649 | 24,649 | 22,713 | 21,666 | 21,926 | 21,150 | 20,159 | 19,890 | 18,674 | |
Level 3 Rollforward — Additions ($M)($M) | 0 | 0 | 0 | 0 | 0 | 78 | 0 | 0 | 0 | 0 | |||
Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M)($M) | 1,518 | 2,387 | 1,406 | 776 | 2,795 | 1,518 | 279 | 1,356 | 1,476 | 660 | 1,696 | 8 | |
Level 3 Rollforward — Cash Settlements and Payments ($M)($M)1 | 1,062 | 722 | 681 | 776 | 859 | 549 | 539 | 580 | 485 | 391 | 480 | 485 | |
Contingent Consideration Payments — Operating Cash Flow Portion ($M)($M) | 1,062 | 722 | 681 | 776 | 859 | 549 | 539 | 580 | 485 | 391 | 463 | 391 | |
Valuation Inputs — Discount Rate Minimum (%)(%) | 4.2% | 4.1% | 4.8% | 3.8% | 4.0% | 4.2% | 4.6% | 3.9% | 4.8% | 4.6% | 4.3% | 5.3% | |
Valuation Inputs — Discount Rate Maximum (%)(%) | 5.5% | 5.0% | 3.7% | 4.6% | 4.8% | 4.9% | 5.2% | 5.1% | 5.9% | 5.8% | 5.9% | 6.1% | |
Valuation Inputs — Discount Rate Weighted Average (%)(%) | 4.5% | 4.3% | 4.0% | 4.1% | 4.3% | 4.5% | 4.8% | 4.1% | 5.0% | 4.8% | 4.5% | 5.5% | |
Valuation Inputs — Payment Probability Maximum (%)(%) | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
Valuation Inputs — Payment Probability Weighted Average (%)(%) | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.0% | 99.0% | 99.0% | |
Recorded Litigation Accrual Reserve ($M)($M)4 | 1,700 | 1,700 | 1,600 | 1,500 | 1,800 | 1,800 | 2,500 | 2,400 | 2,000 | ||||
Net Litigation Reserve Charges / Adjustments ($M)($M) | -64 | 150 | 136 | -319 | -21 | -729 | 167 | 314 | 39 | -12 | -238 | -87 | |
Pending Legal Claims — Prescription Opioid Lawsuits Total (cases)2 | 215 | 320 | 335 | 380 | 380 | 430 | 435 | 440 | 460 | 580 | 590 | 610 | |
Pending Claims — Prescription Opioid State Lawsuits (cases) | 20 | 20 | 25 | 25 | 25 | 30 | 35 | 35 | 45 | 165 | 175 | 160 | |
Pending Claims — Prescription Opioid Municipal & Local Lawsuits (cases) | 20 | 20 | 20 | 20 | 20 | 25 | 25 | 30 | |||||
Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases) | 475 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | ||||
Pending Legal Claims — Other Product Liability Lawsuits (cases)1 | 1,300 | 1,320 | 1,320 | 1,300 | 1,290 | 1,260 | 1,100 | 1,000 | 1,000 | ||||
Pending Claims — International Product Liability Lawsuits (cases) | 1,080 | 1,080 | 1,080 | 1,025 | 1,005 | 1,000 | 1,000 | 800 | 800 | ||||
Inventories, Net ($M)($M)3 | 5,127 | 5,049 | 4,951 | 4,938 | 4,960 | 4,526 | 4,181 | 4,450 | 4,218 | 4,245 | 4,099 | 3,981 | |
Finished Goods ($M)($M) | 1,671 | 1,806 | 1,580 | 1,579 | 1,681 | 1,441 | 1,173 | 1,347 | 1,189 | 1,258 | 1,356 | 1,035 | |
Work in Process ($M)($M) | 2,316 | 2,137 | 2,287 | 2,277 | 2,113 | 1,974 | 1,951 | 2,071 | 1,930 | 1,890 | 1,643 | 1,690 | |
Raw Materials ($M)($M) | 1,140 | 1,106 | 1,084 | 1,082 | 1,166 | 1,111 | 1,057 | 1,032 | 1,099 | 1,097 | 1,100 | 1,256 | |
Property, Plant and Equipment, Net ($M)($M)4 | 5,796 | 5,687 | 5,628 | 5,483 | 5,283 | 5,237 | 5,134 | 5,141 | 5,023 | 4,980 | 4,989 | 4,934 | |
Property, Plant and Equipment, Gross ($M)($M) | 13,955 | 13,731 | 13,530 | 13,229 | 12,934 | 12,571 | 12,267 | 12,279 | 11,903 | 11,725 | 11,635 | 11,374 | |
Accumulated Depreciation ($M)($M) | 8,159 | 8,044 | 7,902 | 7,746 | 7,651 | 7,334 | 7,133 | 7,138 | 6,880 | 6,745 | 6,646 | 6,440 | |
Depreciation Expense ($M)($M) | 194 | 188 | 203 | 192 | 186 | 181 | 206 | 191 | 184 | 183 | 187 | 196 | |
Capital Expenditures ($M)($M) | 322 | 265 | 329 | 381 | 269 | 235 | 291 | 249 | 241 | 193 | 205 | 219 | |
Intangible Assets, Net ($M)($M)4 | 49,139 | 50,873 | 52,641 | 54,315 | 57,031 | 58,489 | 60,068 | 66,646 | 60,243 | 62,225 | 55,610 | 58,603 | |
Goodwill ($M)($M) | 35,519 | 35,570 | 35,640 | 35,626 | 35,638 | 35,285 | 34,956 | 35,295 | 33,386 | 33,426 | 32,293 | 32,091 | |
Definite-Lived Intangible Assets, Net ($M)($M)4 | 44,738 | 45,601 | 47,360 | 49,034 | 51,745 | 53,198 | 54,866 | 56,951 | 58,663 | 60,645 | 55,307 | 58,318 | |
Developed Product Rights, Net ($M)($M)2 | 44,077 | 44,785 | 46,390 | 47,874 | 50,396 | 51,657 | 53,175 | 54,998 | 56,446 | 58,160 | 52,687 | 55,356 | |
Developed Product Rights, Gross ($M)($M) | 81,968 | 81,165 | 81,239 | 81,126 | 82,150 | 81,638 | 81,428 | 81,721 | 81,497 | 82,219 | 75,142 | 76,526 | |
Developed Product Rights, Accumulated Amortization ($M)($M) | 37,891 | 36,380 | 34,849 | 33,252 | 31,754 | 29,981 | 28,253 | 26,723 | 25,051 | 24,059 | 22,455 | 21,170 | |
License Agreements, Net ($M)($M)2 | 661 | 816 | 970 | 1,160 | 1,349 | 1,541 | 1,691 | 1,953 | 2,217 | 2,485 | 2,620 | 2,962 | |
License Agreements, Gross ($M)($M) | 8,359 | 8,359 | 8,353 | 8,353 | 8,352 | 8,352 | 8,315 | 8,316 | 8,315 | 8,316 | 8,191 | 8,261 | |
License Agreements, Accumulated Amortization ($M)($M) | 7,698 | 7,543 | 7,383 | 7,193 | 7,003 | 6,811 | 6,624 | 6,363 | 6,098 | 5,831 | 5,571 | 5,299 | |
Definite-Lived Intangible Assets, Gross ($M)($M) | 90,327 | 89,524 | 89,592 | 89,479 | 90,502 | 89,990 | 89,743 | 90,037 | 89,812 | 90,535 | 83,333 | 84,787 | |
Definite-Lived Intangible Assets, Accumulated Amortization ($M)($M) | 45,589 | 43,923 | 42,232 | 40,445 | 38,757 | 36,792 | 34,877 | 33,086 | 31,149 | 29,890 | 28,026 | 26,469 | |
Indefinite-Lived IPR&D Intangible Assets ($M)($M) | 4,401 | 5,272 | 5,281 | 5,281 | 5,286 | 5,291 | 5,202 | 9,695 | 1,580 | 1,580 | 303 | 285 | |
Intangible Asset Amortization Expense ($M)($M) | 1,700 | 1,700 | 1,800 | 1,900 | 1,900 | 1,900 | 1,900 | 1,900 | 1,900 | 1,900 | 1,800 | 2,000 | |
Long-Term Debt and Finance Lease Obligations, Noncurrent ($M)($M)2 | 62,481 | 64,532 | 58,941 | 62,971 | 62,959 | 64,527 | 60,340 | 58,509 | 58,048 | 63,805 | 52,194 | 55,631 | |
Current Portion of Long-Term Debt and Finance Leases ($M)($M) | 8,341 | 8,326 | 6,056 | 1,982 | 1,966 | 3,769 | 6,804 | 12,570 | 12,586 | 10,193 | 7,191 | 5,113 | |
Short-Term Borrowings ($M)($M) | 0 | 0 | 2,499 | 3,790 | 5,556 | 1,593 | 0 | 3 | 0 | 2 | |||
Cash Dividends Declared ($M)($M)6 | 3,074 | 3,074 | 3,075 | 2,917 | 2,914 | 2,913 | 2,914 | 2,757 | 2,754 | 2,753 | 2,755 | 2,634 | |
Dividends Declared per Common Share ($/sh)($) | 1.73 | 1.73 | 1.73 | 1.64 | 1.64 | 1.64 | 1.64 | 1.55 | 1.55 | 1.55 | 1.55 | 1.48 | |
Cash Paid for Purchases of Common Stock ($M)($M) | 9 | 1,489 | 3 | 4 | 12 | 961 | 358 | 17 | 9 | 1,324 | 3 | 4 | |
Common Stock Held in Treasury (M shares) | 77.10 | 77.10 | 70.80 | 70.80 | 70.80 | 70.80 | 66.30 | 64.30 | 64.30 | 64.20 | 57.10 | 57.10 | |
Treasury Stock Carrying Value ($M)($M) | 10,618 | 10,611 | 9,146 | 9,143 | 9,147 | 9,137 | 8,201 | 7,848 | 7,838 | 7,829 | 6,533 | 6,525 | |
Stock-Based Compensation Expense ($M)($M) | 166 | 444 | 157 | 209 | 179 | 410 | 164 | 181 | 218 | 348 | 125 | 130 | |
Stock-Based Compensation Tax Benefit ($M)($M) | 29 | 75 | 31 | 35 | 34 | 70 | 32 | 33 | 34 | 60 | 25 | 26 | |
Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) [year-end] ($M)4 | |||||||||||||
Net Periodic Pension Benefit Cost ($M)($M) | -14 | -31 | -14 | -13 | -6 | -20 | 1 | 1 | 1 | 1 | -1 | -1 | |
Pension Service Cost ($M)($M) | 68 | 63 | 67 | 66 | 68 | 63 | 72 | 71 | 71 | 72 | 67 | 68 | |
Pension Interest Cost ($M)($M) | 128 | 122 | 121 | 122 | 124 | 117 | 112 | 113 | 113 | 113 | 108 | 108 | |
Expected Return on Pension Plan Assets ($M)($M) | 222 | 224 | 209 | 209 | 208 | 206 | 196 | 196 | 196 | 197 | 180 | 181 | |
Other Post-Employment Benefit (OPEB) Plans — Benefit Obligation [year-end] ($M)3 | |||||||||||||
Net Periodic OPEB Cost ($M)($M) | 13 | 15 | 15 | 15 | 14 | 14 | 16 | 16 | 17 | 16 | 13 | 12 | |
OPEB Service Cost ($M)($M) | 10 | 11 | 10 | 10 | 10 | 10 | 11 | 11 | 10 | 11 | 10 | 9 | |
OPEB Interest Cost ($M)($M) | 10 | 11 | 11 | 11 | 11 | 11 | 10 | 10 | 11 | 10 | 9 | 9 | |
Income Tax Expense ($M)($M)1 | 662 | 342 | 853 | 526 | 613 | 372 | -2,246 | 520 | 773 | 383 | 388 | 172 | |
Deferred Income Tax Expense (Benefit) ($M)($M) | -195 | 137 | -385 | 193 | -272 | -28 | -767 | -277 | -16 | -389 | -1,391 | -863 | |
PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100) | 926.70 | 925.40 | 919.10 | 917.40 | 915.10 | 915.30 | 918.10 | 917.30 | 914.40 | 907.80 | 896.30 | 896.50 | |
U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M)($M)1 | 97,481 | 95,519 | 103,201 | 102,234 | 100,190 | 98,467 | 97,365 | 95,992 | 89,716 | 87,927 | 89,673 | 85,816 | |
U.S. Retail Sales: Pharmacies and Drug Stores — Not Seasonally Adjusted ($M)($M) | 97,059 | 93,047 | 106,419 | 102,171 | 99,818 | 95,892 | 100,312 | 95,792 | 89,173 | 86,987 | 91,914 | 85,089 | |
Income Statement — Net revenues ($M)($M)14 | 16,990 | 15,002 | 16,618 | 15,776 | 15,423 | 13,343 | 15,102 | 14,460 | 14,462 | 12,310 | 14,301 | 13,927 | |
Cost of products sold ($M)($M) | 4,291 | 4,218 | 4,552 | 5,304 | 4,346 | 4,002 | 4,396 | 4,212 | 4,202 | 4,094 | 5,704 | 6,485 | |
Total operating costs and expenses ($M)($M) | 10,558 | 11,012 | 12,074 | 13,872 | 10,529 | 9,610 | 16,592 | 10,629 | 10,464 | 9,512 | 11,106 | 11,646 | |
Selling, general and administrative expense ($M)($M) | 3,632 | 3,578 | 3,895 | 3,569 | 3,253 | 3,293 | 3,855 | 4,205 | 3,377 | 3,315 | 3,193 | 3,372 | |
Research and development expense ($M)($M) | 2,344 | 2,472 | 2,579 | 2,319 | 2,131 | 2,067 | 6,774 | 2,130 | 1,948 | 1,939 | 1,927 | 1,723 | |
Operating earnings ($M)($M) | 6,432 | 3,990 | 4,544 | 1,904 | 4,894 | 3,733 | -1,490 | 3,831 | 3,998 | 2,798 | 3,195 | 2,281 | |
Interest expense ($M)($M) | 746 | 717 | 714 | 739 | 740 | 700 | 702 | 720 | 726 | 660 | 564 | 555 | |
Interest income ($M)($M) | 67 | 72 | 59 | 72 | 62 | 73 | 92 | 129 | 220 | 207 | 186 | 157 | |
Earnings before income tax ($M)($M) | 4,278 | 1,039 | 2,668 | 714 | 1,554 | 1,661 | -2,269 | 2,084 | 2,146 | 1,755 | 1,212 | 1,953 | |
Income tax expense ($M)($M) | 662 | 342 | 853 | 526 | 613 | 372 | -2,246 | 520 | 773 | 383 | 388 | 172 | |
Net earnings attributable to AbbVie Inc. ($M)($M) | 3,601 | 685 | 1,806 | 176 | 928 | 1,276 | -32 | 1,551 | 1,360 | 1,359 | 811 | 1,767 | |
Earnings per share — Basic ($/sh)($) | 2.04 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 | 0.88 | 0.77 | 0.77 | 0.46 | 1 | |
Earnings per share — Diluted ($/sh)($) | 2.03 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 | 0.88 | 0.77 | 0.77 | 0.46 | 1 | |
Weighted-average basic shares outstanding (M) | 1,769.00 | 1,770.00 | 1,769.00 | 1,768.00 | 1,768.00 | 1,769.00 | 1,768.00 | 1,769.00 | 1,767.00 | ||||
Weighted-average diluted shares outstanding (M) | 1,771.00 | 1,774.00 | 1,772.00 | 1,771.00 | 1,772.00 | 1,772.00 | 1,771.00 | 1,773.00 | 1,771.00 | ||||
Balance Sheet — Total assets ($M)($M)12 | 135,115 | 136,463 | 133,960 | 133,898 | 137,182 | 136,165 | 135,161 | 143,422 | 141,937 | 148,874 | 134,711 | 136,221 | |
Cash and equivalents ($M)($M) | 6,569 | 9,391 | 5,229 | 5,629 | 6,467 | 5,175 | 5,524 | 7,257 | 13,130 | 18,067 | 12,814 | 13,287 | |
Accounts receivable, net ($M)($M) | 13,824 | 12,479 | 12,589 | 12,769 | 12,637 | 12,477 | 10,919 | 11,472 | 11,724 | 11,949 | 11,155 | 11,412 | |
Inventories ($M)($M) | 5,127 | 5,049 | 4,951 | 4,938 | 4,960 | 4,526 | 4,181 | 4,450 | 4,218 | 4,245 | 4,099 | 3,981 | |
Total current assets ($M)($M) | 33,669 | 33,529 | 29,062 | 28,539 | 29,261 | 27,675 | 25,582 | 27,785 | 33,816 | 38,871 | 33,002 | 33,224 | |
Property and equipment, net ($M)($M) | 5,796 | 5,687 | 5,628 | 5,483 | 5,283 | 5,237 | 5,134 | 5,141 | 5,023 | 4,980 | 4,989 | 4,934 | |
Goodwill ($M)($M) | 35,519 | 35,570 | 35,640 | 35,626 | 35,638 | 35,285 | 34,956 | 35,295 | 33,386 | 33,426 | 32,293 | 32,091 | |
Intangible assets, net ($M)($M) | 49,139 | 50,873 | 52,641 | 54,315 | 57,031 | 58,489 | 60,068 | 66,646 | 60,243 | 62,225 | 55,610 | 58,603 | |
Accounts payable ($M)($M) | 33,301 | 33,774 | 34,734 | 33,619 | 32,245 | 31,041 | 2,945 | 30,492 | 29,329 | 31,326 | 3,688 | 29,658 | |
Total current liabilities ($M)($M) | 41,642 | 42,100 | 43,289 | 39,391 | 39,767 | 36,403 | 38,749 | 43,062 | 41,915 | 41,522 | 37,841 | 34,773 | |
Long-term debt and finance lease obligations ($M)($M) | 62,481 | 64,532 | 58,941 | 62,971 | 62,959 | 64,527 | 60,340 | 58,509 | 58,048 | 63,805 | 52,194 | 55,631 | |
Retained earnings ($M)($M) | -17,333 | -17,872 | -15,493 | -14,234 | -11,503 | -9,527 | -7,900 | -4,964 | -3,768 | -2,384 | -1,000 | 933 | |
Total stockholders' equity (deficit) ($M)($M) | -5,888 | -6,612 | -3,228 | -2,599 | -138 | 1,462 | 3,364 | 6,071 | 6,821 | 8,047 | 10,397 | 12,129 | |
Cash Flow Statement — Operating cash flow ($M)($M)3 | 3,436 | 3,829 | 5,218 | 7,024 | 5,153 | 1,635 | 7,048 | 5,447 | 2,271 | 4,040 | 4,753 | 7,574 | |
Capital expenditures ($M)($M) | 322 | 265 | 329 | 381 | 269 | 235 | 291 | 249 | 241 | 193 | 205 | 219 | |
Cash dividends paid ($M)($M) | 3,070 | 3,086 | 2,911 | 2,911 | 2,910 | 2,925 | 2,752 | 2,751 | 2,750 | 2,772 | 2,626 | 2,627 | |
Purchases of common stock ($M)($M) | 9 | 1,489 | 3 | 4 | 12 | 961 | 358 | 17 | 9 | 1,324 | 3 | 4 | |
74 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: AbbVie Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). AbbVie operates as a single global biopharmaceutical operating segment (Note 16), so commercial performance is tracked through Therapeutic Area portfolios and brand-level Worldwide / U.S. / International net revenues.
- Core commercial & R&D KPIs (Groups 1–8) cover: (1) Consolidated Net Revenues ($17,264M in Q2 2026 / $61,160M in FY25 across U.S. $13,074M and International $4,190M in Q2 2026; +12.0% reported / +11.4% operational YoY), 12-country annual revenue disaggregation (U.S. $47,125M, Germany $1,622M, Japan $1,182M, Canada $1,167M, China $1,111M, France $963M, U.K. $763M, Spain $726M, Italy $650M, Brazil $544M, Australia $447M, Other $4,860M in FY25), and geographic long-lived assets ($11,833M in FY25); (2) Immunology Portfolio ($8,786M in Q2 2026 / $30,406M in FY25, +16.9% reported / +16.4% operational in Q2 2026: Skyrizi $5,505M, Rinvoq $2,525M, Humira $756M); (3) Neuroscience Portfolio ($3,228M in Q2 2026 / $10,767M in FY25, +20.3% reported / +19.8% operational: Vraylar $1,071M, Botox Therapeutic $1,042M, Ubrelvy $392M, Qulipta $350M, Vyalev $256M, Other Neuroscience $117M, plus Duodopa through Q4 2025); (4) Oncology Portfolio ($1,650M in Q2 2026 / $6,655M in FY25: Venclexta $771M, Imbruvica $532M, Elahere $211M, Epkinly $103M, Other Oncology $33M); (5) Aesthetics Portfolio ($1,269M in Q2 2026 / $4,854M in FY25: Botox Cosmetic $728M, Juvederm $245M, Other Aesthetics $296M), Other Key Products (Mavyret $319M, Creon $323M, Linzess/Constella $310M, All Other $1,379M in Q2 2026), Eye Care Portfolio ($2,068M in FY25: Ozurdex $497M, Lumigan/Ganfort $436M, Alphagan/Combigan $231M, Other Eye Care $904M; folded into All Other in Q1 2026), and legacy discontinued franchises; (6) Gross-to-Net (GTN) provisions ($44.9B rebates & chargebacks and $3.27B cash discounts in FY25), Accrued Sales Rebates ($17,032M at FY25), 14-year rollforwards of Medicaid/Medicare ($2,115M ending FY25), Managed Care ($13,544M ending FY25) & Wholesaler Chargebacks ($1,373M ending FY25), and U.S. wholesaler AR concentration (85% in FY25); (7) R&D & Acquired IPR&D ($2,356M GAAP / $2,315M Adjusted R&D and $142M upfront + $50M milestone IPR&D in Q2 2026; Janssen Imbruvica & Genentech Venclexta collaboration profit shares); and (8) GAAP vs. Non-GAAP margins (85.1% Adjusted Gross Margin, 48.0% Adjusted Operating Margin, $3.35 Adjusted Diluted EPS in Q2 2026; $10.00 Adjusted Diluted EPS in FY25) and Specified Items.
- Groups 9–12 cover: (9) Level 3 Contingent Consideration Liabilities ($26,010M at Q2 2026; Skyrizi/Risankizumab additions, fair value changes, cash payments & discount rate / probability valuation inputs), Litigation Accrual Reserve ($1,395M at Q2 2026) and pending legal claims (Opioid, Biocell ALCL, Product Liability, Niaspan); (10) Inventories by stage ($5,112M net at Q2 2026: Finished Goods $1,427M, WIP $2,310M, Raw Materials $1,375M), PP&E by category ($6,456M net at Q2 2026; 272 facilities / 23M sq ft in FY25), Goodwill ($35,610M) & Intangibles ($54,752M net at Q2 2026 with 5-year estimated amortization schedule), and Operating Leases; (11) Debt & 5-year maturity schedule ($60,646M noncurrent long-term debt at Q2 2026), Capital Return ($3,081M dividends declared / $1.73 per share in Q2 2026; treasury stock & SBC), Defined Benefit Pension ($10,031M PBO / $11,226M plan assets / +$1,195M funded status at FY25) & OPEB plans, and Income Taxes (DTA/DTL breakdown & UTB rollforward $2,756M at FY25); and (12) Global Workforce (55,000 employees, 8% turnover, 34% internal hire rate, 6,500 new hires, 55% women globally, 58% women in STEM in FY25), CEO Pay Ratio (251:1 / $133,895 median employee in FY25), Form 11-K AbbVie Savings Plan ($14.80B net assets at FY25), Workplace Safety (0.11 TRIR / 0.04 LTIR in FY25), Product Quality (55 external / 7 FDA inspections in FY25), Form SD 3TG Suppliers (73 suppliers / 86% response rate in FY25), and Scope 1 & 2 GHG Emissions, Energy, Water & Waste.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as '>100.0%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-10-26.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Consolidated Net Revenues, Country Disaggregation & Geographic Long-Lived Assets
Immunology Portfolio Net Revenues & Operational Growth (Skyrizi, Rinvoq, Humira)
Neuroscience Portfolio Net Revenues & Operational Growth (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev)
Oncology Portfolio Net Revenues & Operational Growth (Venclexta, Imbruvica, Elahere, Epkinly)
Aesthetics, Other Key Products (Mavyret, Creon, Linzess), Eye Care & Legacy Product Portfolios
- Aesthetics Portfolio — Worldwide net revenues ($M) ($M)25 kỳ
- Other Key Products Portfolio — Worldwide net revenues ($M) ($M)32 kỳ
- Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M)23 kỳ
- Lupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M)20 kỳ
- Synthroid (levothyroxine) [legacy through FY21] — Worldwide net revenues ($M) ($M)20 kỳ
- Women's Health Portfolio [legacy through FY21] — Worldwide net revenues ($M) ($M)7 kỳ
- Kaletra (lopinavir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)13 kỳ
- Sevoflurane [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)13 kỳ
- AndroGel (testosterone gel) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)13 kỳ
- Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)10 kỳ
- Synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M)13 kỳ
Gross-to-Net (GTN) Sales Rebates, Chargebacks, Discounts & Wholesaler Concentration
R&D Innovation, Acquired IPR&D Milestones & Strategic Oncology Collaborations (Janssen, Genentech)
- Research and Development (R&D) Expense — GAAP ($M) ($M)46 kỳ
- Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M)46 kỳ
- Janssen Biotech Collaboration (Imbruvica) — International Profit Share in Net Revenues ($M) ($M)29 kỳ
- Genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M) ($M)29 kỳ
GAAP vs. Non-GAAP Operational Margins, Specified Items & Earnings Reconciliation
- Adjusted Gross Margin Ratio — Non-GAAP (%) (%)33 kỳ
- Adjusted Operating Margin Ratio — Non-GAAP (%) (%)33 kỳ
- Adjusted SG&A Expense % of Net Revenues — Non-GAAP (%) (%)16 kỳ
- Adjusted Effective Tax Rate — Non-GAAP (%) (%)24 kỳ
- Adjusted After-Tax Earnings — Non-GAAP ($M) ($M)16 kỳ
- Adjusted Diluted Earnings Per Share — Non-GAAP ($/sh) ($)18 kỳ
Contingent Consideration Liabilities (Level 3 Rollforward & Valuation Inputs), Litigation & Restructuring
Inventories by Stage, PP&E & Facilities, Goodwill & Intangibles (5-Year Amortization) & Leases
Debt & 5-Year Maturity Schedule, Capital Return, Defined Benefit Pension/OPEB & Income Taxes
- Long-Term Debt and Finance Lease Obligations, Noncurrent ($M) ($M)46 kỳ
- Cash Dividends Declared ($M) ($M)34 kỳ
- Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) [year-end] ($M) ($M)11 kỳ
- Other Post-Employment Benefit (OPEB) Plans — Benefit Obligation [year-end] ($M) ($M)11 kỳ
- Income Tax Expense ($M) ($M)46 kỳ
Global Workforce, Diversity, 401(k) Savings Plan, Safety, Quality & Environmental Sustainability (ESG)
- Global Workforce — Total Employees (employees)11 kỳ
- CEO Pay Ratio (x:1)7 kỳ
- AbbVie Savings Plan (Form 11-K) — Net Assets Available for Benefits ($K)5 kỳ
- Workplace Safety — Recordable Incident Rate (TRIR per 200,000 hours worked)5 kỳ
- Product Quality — External Regulatory Inspections of Commercial Manufacturing (inspections)5 kỳ
- Climate — Absolute Scope 1 GHG Emissions (tCO2e)5 kỳ
- Climate — Absolute Scope 2 Market-Based GHG Emissions (tCO2e)5 kỳ
- Energy — Absolute Total Energy Consumption (MWh)5 kỳ
- Water — Absolute Water Withdrawal (M m3)4 kỳ
- Waste — Absolute Total Hazardous and Non-Hazardous Waste Generated (k metric tons)5 kỳ
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)
- PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100)129 kỳ
- U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M) ($M)128 kỳ
- Income Statement — Net revenues ($M) ($M)58 kỳ
- Balance Sheet — Total assets ($M) ($M)55 kỳ
- Cash Flow Statement — Operating cash flow ($M) ($M)58 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của AbbVie
- Form 10-Q (filed 2026-08-03) ↗
- Form 10-K (filed 2026-02-20) ↗
- Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
- Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
- Form 10-K (filed 2020-02-21) ↗
- AbbVie 2025 ESG Action Report ↗
- Form 10-Q (filed 2020-05-08) ↗
- Form 10-K (abbv-20251231.htm, filed 2026-02-20) ↗
- Form 10-K (filed 2022-02-18) ↗
- FRED (PCU325412325412) ↗
- FRED (MRTSSM44611USS) ↗
- Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
See a number that looks wrong?